Skip to main content
Retour
ALVO logo

Alvotech

Qualité des données : 100%
Survendu
ALVO
NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
3,13 €
▼ 0,20 € (-6,01%)
Cap. Boursière : 975,31M
Fourchette du Jour
3,03 € 3,28 €
Fourchette 52 Semaines
3,03 € 11,85 €
Volume
1 130 277
Moyenne 50J / 200J
4,53 € / 6,85 €
Clôture Précédente
3,33 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E -4,2 0,3
P/B 2,9
ROE % 3,7
Net Margin % -47,4 3,8
Rev Growth 5Y % 64,7 10,0
D/E 0,2

Objectif de Cours des Analystes

Hold
8,60 € +174.8%
Low: 5,00 € High: 10,00 €
P/E Prévisionnel
37,0
BPA Prévisionnel
0,09 €
Croissance BPA (est.)
+0,0%
CA Est.
640 M

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 2,08 €
1,62 € – 2,49 €
1,7 B 1
FY2029 1,17 €
0,91 € – 1,40 €
1,4 B 1
FY2028 0,56 €
0,15 € – 0,97 €
1 B 2

Points Clés

Revenue grew 64,66% annually over 5 years — strong growth
Negative free cash flow of -293,84M
PEG of 0,24 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 370,90%
Interest coverage of 0,44× — tight debt servicing

Croissance

Revenue Growth (5Y)
64,66%
Revenue (1Y)435,56%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
N/A
ROIC6,72%
Net Margin-47,35%
Op. Margin14,22%

Sécurité

Debt / Equity
N/A
Current Ratio2,35
Interest Coverage0,44

Valorisation

P/E Ratio
-4,21
P/B RatioN/A
EV/EBITDA30,36
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 435,56% Revenue Growth (3Y) 142,85%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 64,66% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 489,68M Net Income (TTM) -231,86M
ROE N/A ROA -18,98%
Gross Margin 62,16% Operating Margin 14,22%
Net Margin -47,35% Free Cash Flow (TTM) -293,84M
ROIC 6,72% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 2,35
Interest Coverage 0,44 Dividend Yield 0,00%
Valuation
P/E Ratio -4,21 P/B Ratio N/A
P/S Ratio 1,99 PEG Ratio 0,24
EV/EBITDA 30,36 Dividend Yield 0,00%
Market Cap 975,31M Enterprise Value 2,11B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 489,68M 91,43M 83,03M 36,77M 66,62M
Net Income -231,86M -551,73M -513,58M -101,50M -170,04M
EPS (Diluted) -0,87 -2,43 -2,60 -3,25 -5,44
Gross Profit 304,37M -69,42M 18,93M 36,77M 66,62M
Operating Income 69,64M -354,86M -346,44M -235,46M -137,54M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 1,22B 950,09M 828,44M 597,98M 474,42M
Total Liabilities 1,63B 1,88B 1,39B 733,59M 1,34B
Shareholders' Equity -412,77M -932,49M -564,42M -135,61M -867,24M
Total Debt 1,19B 1,08B 805,10M 523,05M 676,85M
Cash & Equivalents 51,43M 11,16M 66,43M 17,56M 31,69M
Current Assets 455,02M 194,84M 230,74M 119,82M 86,16M
Current Liabilities 193,40M 260,95M 167,29M 111,84M 50,98M